BCL2L11 (BIM) deletion polymorphism, rather than BIM SNP, is an effective predictor of early molecular relapse after ABL tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia
Year: 2015
Type: article
Study design: Observational Study
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2547657555
